| Name | Title | Contact Details |
|---|
The future of medical image management is in the cloud. Unfortunately, the farther data travels the more lag time accrues. We call this latency. Radiologists and other physicians are accustomed to receiving images at rates of 50 frames per second. When traveling across the entire United States, it may drop to 10 frames per second - much too slow for acceptable patient care. NucleusHealth™ overcomes latency via our patent-pending streaming protocols, client-side rendering techniques, modern web browser technologies, and the computing horsepower of todays phones, laptops and desktops. Diagnostic quality images come to life on displays at blazing-fast speeds. Even large file types such as digital breast tomosynthesis can be displayed in seconds, not minutes. With that single achievement, NucleusHealth sets a new standard for performance, scalability, security, high availability and response times. Faster, more accurate care means better outcomes at a lower cost. The next generation of medical image management has been born.
Whitecourts Interagency Food Bank is a Whitecourt, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cancer Expert Now`s services connect you to distinguished experts to discuss current disease challenges, recent literature, global clinical findings, and even share their research and experience in the context of your specific diagnosis, or patient cases.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
paramedics plus is a Tyler, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.